Hologic, Inc. (NASDAQ:HOLX) Shares Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue lessened its holdings in Hologic, Inc. (NASDAQ:HOLX) by 10.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 189,229 shares of the medical equipment provider’s stock after selling 22,270 shares during the period. State of Alaska Department of Revenue owned approximately 0.08% of Hologic worth $15,413,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Wealth Enhancement Advisory Services LLC boosted its stake in Hologic by 55.1% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 7,449 shares of the medical equipment provider’s stock worth $607,000 after buying an additional 2,645 shares during the period. Forsta AP Fonden boosted its position in shares of Hologic by 11.3% during the 3rd quarter. Forsta AP Fonden now owns 49,300 shares of the medical equipment provider’s stock worth $4,016,000 after purchasing an additional 5,000 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Hologic by 25.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,114 shares of the medical equipment provider’s stock valued at $1,706,000 after purchasing an additional 4,314 shares during the last quarter. Cromwell Holdings LLC raised its position in Hologic by 330.2% in the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 416 shares during the period. Finally, Legacy Wealth Asset Management LLC lifted its stake in Hologic by 13.6% during the third quarter. Legacy Wealth Asset Management LLC now owns 4,158 shares of the medical equipment provider’s stock worth $339,000 after purchasing an additional 499 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research note on Tuesday, October 15th. Evercore ISI boosted their price target on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. Citigroup lowered shares of Hologic from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Royal Bank of Canada restated a “sector perform” rating and issued a $82.00 price objective on shares of Hologic in a report on Friday, August 16th. Finally, Stephens reiterated an “overweight” rating and set a $92.00 target price on shares of Hologic in a report on Tuesday, July 30th. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $87.50.

Hologic Price Performance

Shares of HOLX opened at $80.83 on Friday. The firm has a market capitalization of $18.77 billion, a price-to-earnings ratio of 27.49, a PEG ratio of 2.96 and a beta of 0.98. The firm’s fifty day simple moving average is $80.92 and its 200-day simple moving average is $77.86. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $84.67. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. Hologic’s quarterly revenue was up 2.7% on a year-over-year basis. During the same period last year, the firm earned $0.93 earnings per share. Equities analysts forecast that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

Insider Transactions at Hologic

In related news, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the completion of the transaction, the insider now directly owns 10,476 shares of the company’s stock, valued at $858,927.24. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the sale, the insider now directly owns 10,476 shares in the company, valued at $858,927.24. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Brandon Schnittker sold 476 shares of the business’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the sale, the insider now directly owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.75% of the company’s stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.